Show simple item record

dc.contributor.authorTian, Bo
dc.contributor.authorBilsbury, Evan
dc.contributor.authorDoherty, Sean
dc.contributor.authorTeebagy, Sean
dc.contributor.authorWood, Emma
dc.contributor.authorSu, Wenqi
dc.contributor.authorGao, Guangping
dc.contributor.authorLin, Haijiang
dc.date.accessioned2024-02-06T14:59:29Z
dc.date.available2024-02-06T14:59:29Z
dc.date.issued2022-09-13
dc.identifier.citationTian B, Bilsbury E, Doherty S, Teebagy S, Wood E, Su W, Gao G, Lin H. Ocular Drug Delivery: Advancements and Innovations. Pharmaceutics. 2022 Sep 13;14(9):1931. doi: 10.3390/pharmaceutics14091931. PMID: 36145679; PMCID: PMC9506479.en_US
dc.identifier.issn1999-4923
dc.identifier.doi10.3390/pharmaceutics14091931en_US
dc.identifier.pmid36145679
dc.identifier.urihttp://hdl.handle.net/20.500.14038/53029
dc.description.abstractOcular drug delivery has been significantly advanced for not only pharmaceutical compounds, such as steroids, nonsteroidal anti-inflammatory drugs, immune modulators, antibiotics, and so forth, but also for the rapidly progressed gene therapy products. For conventional non-gene therapy drugs, appropriate surgical approaches and releasing systems are the main deliberation to achieve adequate treatment outcomes, whereas the scope of "drug delivery" for gene therapy drugs further expands to transgene construct optimization, vector selection, and vector engineering. The eye is the particularly well-suited organ as the gene therapy target, owing to multiple advantages. In this review, we will delve into three main aspects of ocular drug delivery for both conventional drugs and adeno-associated virus (AAV)-based gene therapy products: (1) the development of AAV vector systems for ocular gene therapy, (2) the innovative carriers of medication, and (3) administration routes progression.en_US
dc.language.isoenen_US
dc.relation.ispartofPharmaceuticsen_US
dc.relation.urlhttps://doi.org/10.3390/pharmaceutics14091931en_US
dc.rightsCopyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).en_US
dc.rightsAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectadeno-associated virusen_US
dc.subjectadministration routesen_US
dc.subjectgene therapyen_US
dc.subjectmedication carriersen_US
dc.subjectnon-viral vectorsen_US
dc.subjectocular drug deliveryen_US
dc.titleOcular Drug Delivery: Advancements and Innovationsen_US
dc.typeJournal Articleen_US
dc.source.journaltitlePharmaceutics
dc.source.volume14
dc.source.issue9
dc.source.countrySwitzerland
dc.identifier.journalPharmaceutics
refterms.dateFOA2024-02-06T14:59:30Z
dc.contributor.departmentHorae Gene Therapy Centeren_US
dc.contributor.departmentLi Weibo Institute for Rare Diseases Researchen_US
dc.contributor.departmentMicrobiology and Physiological Systemsen_US
dc.contributor.departmentOphthalmology and Visual Sciencesen_US
dc.contributor.departmentT.H. Chan School of Medicineen_US
dc.contributor.studentEvan Bilsbury
dc.contributor.studentSean Doherty
dc.contributor.studentSean Teebagy


Files in this item

Thumbnail
Name:
pharmaceutics-14-01931.pdf
Size:
2.253Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Copyright: © 2022 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
Except where otherwise noted, this item's license is described as Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).